Found: 16
Select item for more details and to access through your institution.
A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 4, p. 485, doi. 10.3390/pharmaceutics13040485
- By:
- Publication type:
- Article
2216-PUB: Patient Preferences for Newer Oral Therapies in Type 2 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-2216-PUB
- By:
- Publication type:
- Article
Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 427, doi. 10.1111/dom.13945
- By:
- Publication type:
- Article
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
1198-P: The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1198-P
- By:
- Publication type:
- Article
1199-P: Analysis of Patient Preferences for Adjunct Therapy to Insulin in T1D.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1199-P
- By:
- Publication type:
- Article
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 9, p. 2190, doi. 10.1111/dom.13351
- By:
- Publication type:
- Article
Population Pharmacokinetic– Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 5, p. 640, doi. 10.1002/jcph.1051
- By:
- Publication type:
- Article
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
- Published in:
- 2017
- By:
- Publication type:
- Erratum
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0141085
- By:
- Publication type:
- Article
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
- Published in:
- 2014
- By:
- Publication type:
- Letter
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.
- Published in:
- Kidney International, 2014, v. 86, n. 5, p. 1057, doi. 10.1038/ki.2014.246
- By:
- Publication type:
- Article
Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial.
- Published in:
- Diabetes Care, 2014, v. 37, n. 5, p. 1480, doi. 10.2337/dc13-2338
- By:
- Publication type:
- Article
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
- Published in:
- Cardiovascular Diabetology, 2014, v. 13, n. 1, p. 2, doi. 10.1186/1475-2840-13-28
- By:
- Publication type:
- Article
Molecular evidence of placental hypoxia in preeclampsia.
- Published in:
- 2005
- By:
- Publication type:
- journal article